
Some patients may experience durable disease control even after discontinuing immune checkpoint inhibitors for side ...
Bottom Line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control. Journal in Which the Study …